First patients to receive new 'ImmTAC' cancer drug in groundbreaking trial
NCT ID NCT07156136
Summary
This is the first-ever study in people for a new drug called IMC-P115C, designed to treat advanced cancers that have a specific marker called PRAME. The main goal is to test the drug's safety and see if it causes any serious side effects when given alone or with standard treatments. The trial will enroll 140 adults with advanced solid tumors who have run out of other treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research South Australia (CRSA)
RECRUITINGAdelaide, 5000, Australia
-
Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
RECRUITINGToulouse, 31059, France
-
Fondazione IRCCS - Istituto Nazionale dei Tumori
RECRUITINGMilan, 20133, Italy
-
Hospital Universitari Vall d Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Ramon y Cajal
RECRUITINGMadrid, 28034, Spain
-
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals
RECRUITINGBarcelona, 08908, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Istituto Europeo di Oncologia
RECRUITINGMilan, 20141, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
RECRUITINGNaples, 80131, Italy
-
Linear Clinical Research ltd.
RECRUITINGNedlands, 06009, Australia
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, 2065, Australia
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
UNICANCER - Centre Leon-Berard (CLB)
RECRUITINGLyon, 69008, France
Conditions
Explore the condition pages connected to this study.